OptiCross™ 18 Peripheral Imaging Catheter

K222568 · Boston Scientific Corporation · OBJ · Sep 23, 2022 · Cardiovascular

Device Facts

• Record ID: K222568
• Device Name: OptiCross™ 18 Peripheral Imaging Catheter
• Applicant: Boston Scientific Corporation
• Product Code: OBJ · Cardiovascular
• Decision Date: Sep 23, 2022
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 870.1200
• Device Class: Class 2

Intended Use

OptiCross™ 18 is intended for intravascular ultrasound examination of peripheral vessels only. Intrasound imaging is indicated in patients who are candidates for transluminal interventional procedures.

Device Story

OptiCross 18 is a sterile, short-rail intravascular ultrasound (IVUS) imaging catheter. It consists of an imaging core with a 30 MHz ultrasonic transducer and a catheter body with a distal imaging window. The device connects to a Motordrive Unit (MDU5 PLUS™) via an electro-mechanical interface. During peripheral vascular procedures, the catheter is flushed with heparinized saline to provide acoustic coupling. The transducer rotates to capture ultrasonic images of vessel interiors. A telescoping section allows 15 cm of linear movement for the imaging core, enabling longitudinal imaging. Radiopaque markers and depth markers assist in positioning. The device is used by physicians in clinical settings to visualize vessel morphology, aiding in the assessment of lesions and guiding interventional procedures. Output is displayed on the IVUS system, assisting clinical decision-making regarding treatment strategy.

Clinical Evidence

No clinical data. Substantial equivalence is supported by non-clinical bench testing, including physical integrity, functionality, and performance evaluations (imaging robustness, catheter robustness, dimensional requirements, and interface compatibility).

Technological Characteristics

30 MHz ultrasonic transducer; short-rail catheter design; telescoping shaft for 15 cm linear movement; electro-mechanical connector for MDU5 PLUS™; radiopaque markers; heparinized saline acoustic coupling; sterile.

Indications for Use

Indicated for intravascular ultrasound examination of peripheral vessels in patients who are candidates for transluminal interventional procedures.

Regulatory Classification

Identification

An intravascular diagnostic catheter is a device used to record intracardiac pressures, to sample blood, and to introduce substances into the heart and vessels. Included in this generic device are right-heart catheters, left-heart catheters, and angiographic catheters, among others.

Predicate Devices

• OptiCross™ 18 Peripheral Imaging Catheter (K160514)

Reference Devices

• OptiCross™ 35 Peripheral Imaging Catheter (K200733)
• OptiCross™ 6 Coronary Imaging Catheter (K213593)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and then the word "ADMINISTRATION" in a smaller font size, also in blue.

September 23, 2022

Boston Scientific Corporation Cassie Clark Regulatory Affairs Specialist II 1 Scimed Place Maple Grove, Minnesota 55311

Re: K222568

Trade/Device Name: OptiCross™ 18 Peripheral Imaging Catheter Regulation Number: 21 CFR 870.1200 Regulation Name: Diagnostic Intravascular Catheter Regulatory Class: Class II Product Code: OBJ, ITX Dated: August 23, 2022 Received: August 24, 2022

Dear Cassie Clark:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Aneesh Deoras Assistant Director Division of Cardiac Electrophysiology, Diagnostics and Monitoring Devices Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K222568

Device Name

OptiCross 18TM Peripheral Imaging Catheter

Indications for Use (Describe)

OptiCross™ 18 is intended for intravascular ultrasound examination of peripheral vessels only. Intrasound imaging is indicated in patients who are candidates for transluminal interventional procedures.

| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
| |

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for Boston Scientific. The text "Boston" is on the top line, and the text "Scientific" is on the bottom line. The text is in a serif font and is blue.

# K222568 510(k) Summary
per 21 CFR §807.92

| Sponsor | Boston Scientific Corporation<br>300 Boston Scientific Way<br>Marlborough, Massachusetts 01752<br>USA | | | |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|------------------|--|
| Contact Name and<br>Information | Cassie Clark<br>One Scimed Place<br>Maple Grove, MN 55311-1566<br>Phone: [phone]<br>e-mail: [e-mail] | | | |
| Prepared by | Cassie Clark<br>August 23, 2022 | | | |
| Proprietary Name | OptiCross™ 18 Peripheral Imaging Catheter | | | |
| Common Name | Diagnostic Intravascular Catheter, Ultrasound Transducer | | | |
| Product Code | OBJ, ITX | | | |
| Classification | Catheter, Ultrasound, Intravascular (OBJ) has been classified as Class<br>II per 21 CFR 870.1200<br>Transducer Ultrasonic (ITX) has been classified as Class II per 21<br>CFR 892.1570 | | | |
| Predicate Device | OptiCross™ 18 Peripheral<br>Imaging Catheter | K160514 | June 22, 2016 | |
| Reference Devices | OptiCross™ 35 Peripheral<br>Imaging Catheter | K200733 | April 17, 2020 | |
| | OptiCross™ 6 Coronary<br>Imaging Catheter | K213593 | January 14, 2022 | |

{4}------------------------------------------------

# Device Description

The OptiCross 18 30 MHz Peripheral Imaging Catheter is a sterile, short rail imaging catheter.

It consists of two main assemblies:

- 1. Imaging Core
- 2. Catheter Body

The imaging core is composed of a hi-torque, flexible, rotating drive cable with a radial looking 30 MHz ultrasonic transducer at the distal tip. An electro-mechanical connector interface at the proximal end of the catheter makes the connection to the Motordrive Unit (MDU5 PLUS™) Instrument. The MDU5 PLUS-catheter interface consists of an integrated mechanical drive socket and electrical connection.

The catheter body is comprised of three sections:

- 1. Distal Imaging Window Lumen
- 2. Proximal Shaft Lumen
- 3. Telescoping Section

The distal imaging window lumen and proximal shaft lumen sections comprise the "working length" of the catheter, and the telescoping section remains outside of the guiding catheter.

The catheter body has a distal imaging window lumen with proximal exit at 1.6 cm from the distal end. A radiopaque (RO) marker is embedded in the catheter body at 0.5 cm from the distal tip. In addition, two insertion depth markers are located on the proximal shaft lumen at 90 cm and 100 cm from the distal tip to aid in estimating catheter position relative to the distal guide catheter tip. The proximal shaft lumen is attached to the telescoping section via a strain relief connection.

The telescoping shaft (section) allows the imaging core to be advanced and retracted for 15 cm of linear movement. The corresponding movement of the transducer occurs from the proximal end of the quidewire exit port to the proximal end of the distal imaging window lumen. The telescope section has proximal markers for lesion length assessment, consisting of a series of marks spaced 1 cm apart on the telescope body.

A flush port with a one-way check valve is used to flush the interior of the catheter body and maintain a flushed condition. The catheter must be flushed with heparinized saline prior to use, as this provides the acoustic coupling media required for ultrasonic imaging. The one-way check valve helps retain saline in the catheter during use.

### Indications for Use / Intended Use

OptiCross 18 is intended for intravascular ultrasound examination of peripheral vessels only. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal interventional procedures.

# Comparison of Technological Characteristics

The OptiCross™ 18 Peripheral Imaging Catheters incorporate substantially equivalent design, materials, fundamental technology, interface with the IVUS imaging system, sterilization process, and intended use as those featured in the predicate; OptiCross™ 18 Peripheral Imaging Catheter K160514.

Minor design modifications are being implemented to the telescope design and the imaging core design to enhance device robustness and ease of use of the telescope. These changes are intended to harmonize design features across BSC's imaging catheter portfolio with the same enhancements previously submitted and reviewed as part of K213593.

{5}------------------------------------------------

## Non-clinical Performance Data

Determination of substantial equivalence is based on an assessment of non-clinical performance bench testing data.

# Bench Testing

Bench testing was performed to evaluate physical integrity, functionality, and performance of the OptiCross™ 18 Peripheral Imaging Catheters. Performance criteria includes imaging robustness requirements, catheter robustness requirements, dimensional requirements, and interface with compatible devices.

# Clinical Testing

Performance testing from clinical studies is not required to demonstrate substantial equivalence of the OptiCross™ 18 Peripheral Imaging Catheters.

# Conclusion

Based on the indications for use, technological characteristics, and performance testing, the OptiCross™ 18 Peripheral Imaging Catheters have been shown to be appropriate for their intended use and are considered to be substantially equivalent to the predicate device; OptiCross™ 18 Peripheral Imaging Catheter K160514.